Experiment: 2LF4

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	2 mM [U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	90% H2O/10% D2O		5.5	ambient	303
2	2D 1H-15N SOFAST HMQC	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	100% D2O		5.5	ambient	303
3	2D 1H-13C HSQC	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	100% D2O		5.5	ambient	303
4	3D CBCA(CO)NH	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	90% H2O/10% D2O		5.5	ambient	303
5	3D HNCO	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	90% H2O/10% D2O		5.5	ambient	303
6	3D HNCA	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	90% H2O/10% D2O		5.5	ambient	303
7	3D HNCACB	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	90% H2O/10% D2O		5.5	ambient	303
8	3D HCCH-TOCSY	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	100% D2O		5.5	ambient	303
9	3D HCCH-TOCSY	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	100% D2O		5.5	ambient	303
10	3D HCCH-COSY	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	100% D2O		5.5	ambient	303
11	3D HCCH-COSY	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	100% D2O		5.5	ambient	303
12	3D 1H-15N NOESY	2 mM [U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	90% H2O/10% D2O		5.5	ambient	303
13	3D 1H-13C NOESY	2 mM [U-98% 13C; U-98% 15N] HIV-1 CA, 25 mM sodium chloride, 25 mM [U-99% 2H] sodium acetate, 10 mM [U-99% 2H] DTT, 0.02 % sodium azide, 0.1 mM AEBSF protease inhibitor, 1 mM [U-99% 2H] EDTA	100% D2O		5.5	ambient	303

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	600

NMR Refinement
Method	Details	Software
simulated annealing	50,000 steps	TopSpin

NMR Ensemble Information
Conformer Selection Criteria	target function
Conformers Calculated Total Number	500
Conformers Submitted Total Number	20
Representative Model	1 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	data analysis	TopSpin	1.3	Bruker Biospin
2	processing	TopSpin	1.3	Bruker Biospin
3	collection	TopSpin	1.3	Bruker Biospin
4	data analysis	NMRDraw		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
5	data analysis	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
6	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
7	chemical shift assignment	XEASY		Bartels et al.
8	data analysis	XEASY		Bartels et al.
9	peak picking	XEASY		Bartels et al.
10	chemical shift assignment	CYANA	2.1	Guntert, Mumenthaler and Wuthrich
11	structure solution	CYANA	2.1	Guntert, Mumenthaler and Wuthrich
12	refinement	CYANA	2.1	Guntert, Mumenthaler and Wuthrich

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.